As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include an interesting article from low- and middle-income countries and a publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: August 2023

Clinical papers

• Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy
  Pagani IS et al. Blood, August 2023 (epub ahead of print)
• Population modelling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
  Garret M et al. Cancer Med, August 2023 (epub ahead of print) – open access publication
• Step-in dosing of bosutinib in patients with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
  Isfort S et al. Ann Hematol, August 2023 (epub ahead of print) – open access publication
• Interferon in chronic myeloid leukemia: Is it useful for treatment-free remission?
  Breccia M and Saglio G. Br J Haematol, August 2023 (epub ahead of print) – open access publication
  
• Reverse transcription can critically impact the diagnostic outcome of BCR::ABL1 quantitative real-time RT-PCR
  Spiess B et al. Cancers(Basel) – open access publication
• Real-world experience with ponatinib therapy in chronic-phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
  Abdelmagid MG et al. Blood Cancer J, August 2023 (epub ahead of print) – open access publication
• Measuring chronic myeloid leukemia TKI-related toxic effects in the real-world:
  a systematic review and critical assessment of content validity of patient-reported outcomes measures - Review
  Smit Y et al. Lancet Haematol, August 2023 (epub ahead of print)
• Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: A National PopulationBased Cohort Study
  Huang CE et al. Oncologist, August 2023 (epub ahead of print) – open access publication
  
• One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission
  Laganà A et al. Eur J Haematol, August 2023 (epub ahead of print)

Scientific papers

• The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associations with each resistance mechanisms
  Leow BCS et al. Sci Rep, Aug 2023 – open access publication
• Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
  Rattigan KM et al. Nat Commun, August 2023 – open access publication
• Food for thought (and CML survival)
  Sezaki M and Huang G. Blood, August 2023
• High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
  Aghel N et al. Leuk Lymphoma, August 2023 (epub ahead of print)
• MEK1/2 regulates normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
  Mazzera L et al. Leukemia, August 2023 – open access publication

Pediatric CML papers

• Chronic myeloid leukemia in children and adolescents - Review
  Gotesman M et al. Adv Pediatr, August 2023 

COVID-19 + CML

• Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era
  Qi F et al. Ann Hematol, August 2023